A cancer drug, a ski coach, an e-motorbike and a security firm: last week's raisers
Cytospire, Carv, Maeving and OnSecurity raised £1.2m to £30.5m each. In all, 141 companies filed £352.7m of new shares from 9 to 15 Nov 2026.
Cytospire is a biotech with a registered office in the North West. The company says it develops T cell engagers that use gamma delta T cells, rather than CD3, to kill cancer cells, aimed at lung, breast, head and neck, gastric, colorectal, bladder, renal and liver cancers among others. The company says these cells release fewer inflammatory cytokines than engagers that use CD3, which it says may lower the risk of a side effect known as cytokine release syndrome. Natalie Mount is the chief executive. Cytospire raised £30.5m in November1, with shares allotted on 5 Nov 2026. An earlier round, £12.0m, was allotted in March 2026.
Carv, registered as Motion Metrics Limited and based in London, makes a coach for skiers. The company says its sensors clip onto each ski boot strap and that it analyses every run, spots patterns and coaches the skier. A pass gives access for an entire year and a pair of sensors, and the company says the year starts on the first day on the slopes. Carv raised £6.4m in October, with shares allotted from 6 to 15 Oct 2026. Its previous round, £2.3m, was allotted in Oct 2024, and its latest accounts show staff growing from 27 to 31 people.
Maeving sells electric motorbikes straight to riders. The company says its motorcycles are built in Coventry and that the bike is delivered to the door and an engineer comes to the customer for maintenance, with no dealerships. It says it will also reimburse the cost of a new owner's CBT. Its range is the RM1S, the RM2 and the Blackout. Maeving raised £2.0m in September, with shares allotted on 30 Sep 2026. Its latest accounts show staff growing from 40 to 53 people.
OnSecurity is paid to break into other companies' systems, with their consent. The company says it works for more than 500 clients and offers AI-augmented penetration testing, combining automated tooling with human testers, and describes that testing as CREST-approved. Conor O'Neill is the co-founder and chief executive. The company has a registered office in Bristol. OnSecurity raised £1.2m in October, with shares allotted on 13 Oct 2026. Its latest accounts show staff growing from 27 to 51 people.
The four filed their share issues at Companies House between 9 and 13 Nov 2026. They were among 141 companies that filed priced share issues from 9 to 15 Nov 2026, worth £352.7m together. The cash ranged from £1.2m at OnSecurity to £30.5m at Cytospire, and the four were spread across the North West, London, the West Midlands and the South West. It was the first priced round in our data for 62 of those companies.
1 Cytospire announced a £61 million Series A on 5 May 2026.
Sources
- cytospire.com/our-approach
- cytospire.com/our-people
- cytospire.com Series A announcement
- getcarv.com
- maeving.com
- maeving.com/designing-the-best-electric-motorcycles
- onsecurity.io
- onsecurity.io/about-onsecurity
- Bradshaw page for Cytospire
- Bradshaw page for Carv
- Bradshaw page for Maeving
- Bradshaw page for OnSecurity
Learn more at bradshawdata.com. Corrections are listed with their dates.